September 2007, established Kyosei Medical Symbiology Institute Corporation.
May 2008, established the BAK Therapy (Cancer Therapy) Immune Cell Culture Center (CPC).
August 2008, the Kibou no mori Clinic (partner of BBT Group), a specialized clinic for immune cell BAK therapy, was opened.
April 2015, established ‘Cell Science’ for cell culture medium research and development.
April 2018, renamed as Bold Biotechnology Co., Ltd.
June 2020, Bold Biotechnology Co., Ltd began production of exosomes.
September 2021, Bold Biotechnology Co., Ltd acquired and merged with BBT-Sendai Manufacturing Center (Aoba, Sendai)
July 2022, the subsidiary of Kyosei Medical Symbiology Institute Corporation in China - 深圳市共生医药科技有限公司 entered into the OTC market in Shenzhen, China.
October 2022, Kyosei Medical Symbiology Institute Corporation restructure as a subsidiary of Bold Biotechnology Co., Ltd.
October 2022, established New Business Co., Ltd for medicine and medical devices wholesale.
November 2022, headquarter of Bold Biotechnology Co., Ltd relocate to Ginza, Tokyo.
December 2022, Bold Biotechnology Co., Ltd formed BBT International Division BBTF.
September 2023, BBT Sendai Manufacturing Center (formerly ‘Cell Science’) achieved ISO9001:2015 certification.
September 2023, BBT established ‘Yantai Sino-Japanese Regenerative Medicine Clinical Science Research and Test Center’ together with Yuhuangding Hospital of Yantai City and Shandong Qilu Cell Therapy Engineering Technology Co., LTD.
